Silexion Therapeutics Ltd. (SLXN)
$0.18+0.00%Close
BUYCRISIS · day 15
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $75,419
- Beta
- -0.25
- P/E (TTM)
- -0.00
- Short % float
- 1188.06%
- Days to cover
- 1.0
- SI change
- +1964.4%
- 1W
- -30.77%
- 1M
- -53.85%
- vs SPY 1W
- -30.63%
- vs SPY 1M
- -56.35%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 4
- VALUE
- 8
- GROWTH
- 31
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-
REV YoY-
ROE-
EPS YoY-
ROA-328.7%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.00
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B2.75
P/FCF-
EV/EBITDA0.05
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E3204.55
ALTMAN Z-
CURR RATIO0.94
ND/EBITDA-
BETA-0.25
Company news
FAQ
- What is LOPJLB’s current signal on SLXN?
- LOPJLB’s latest quantitative signal on Silexion Therapeutics Ltd. (SLXN) is BUY in a CRISIS regime. Signals are updated daily.
- What market regime is SLXN in?
- Silexion Therapeutics Ltd. (SLXN) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Silexion Therapeutics Ltd. (SLXN) do?
- Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates:…